Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.
de la Cruz-Merino L, Gion M, Cruz-Jurado J, Quiroga V, Andrés R, Moreno F, Alonso-Romero JL, Ramos M, Holgado E, Cortés J, López-Miranda E, Henao-Carrasco F, Palazón-Carrión N, Rodríguez LM, Ceballos I, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. de la Cruz-Merino L, et al. Among authors: holgado e. Cancers (Basel). 2021 Oct 29;13(21):5432. doi: 10.3390/cancers13215432. Cancers (Basel). 2021. PMID: 34771596 Free PMC article.
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.
Sampayo-Cordero M, Miguel-Huguet B, Pérez-García J, Páez D, Guerrero-Zotano ÁL, Garde-Noguera J, Aguirre E, Holgado E, López-Miranda E, Huang X, Malfettone A, Llombart-Cussac A, Cortés J. Sampayo-Cordero M, et al. Among authors: holgado e. Contemp Clin Trials Commun. 2020 Nov 28;20:100678. doi: 10.1016/j.conctc.2020.100678. eCollection 2020 Dec. Contemp Clin Trials Commun. 2020. PMID: 33336109 Free PMC article.
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.
de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andrés R, Santisteban M, Ramos M, Holgado E, Cortés J, López-Miranda E, Cortés A, Henao F, Palazón-Carrión N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. de la Cruz-Merino L, et al. Among authors: holgado e. BMC Cancer. 2022 Dec 3;22(1):1258. doi: 10.1186/s12885-022-10363-3. BMC Cancer. 2022. PMID: 36463104 Free PMC article. Clinical Trial.
Influencing cancer treatment.
Holgado E, Perez JM, Wren A, Cortes J, Gomez-Pinillos A. Holgado E, et al. Lancet Oncol. 2015 Dec;16(16):1591-3. doi: 10.1016/S1470-2045(15)00412-X. Lancet Oncol. 2015. PMID: 26678188 No abstract available.
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.
de Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J, Holgado E. de Melo Gagliato D, et al. Among authors: holgado e. Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):527-537. doi: 10.1016/j.bbcan.2017.10.003. Epub 2017 Oct 20. Biochim Biophys Acta Rev Cancer. 2017. PMID: 29061314 Review.
CXCR4 antagonists for treatment of breast cancer.
Cortés J, Holgado E, Perez-Garcia J. Cortés J, et al. Among authors: holgado e. Oncotarget. 2018 Sep 11;9(71):33442-33443. doi: 10.18632/oncotarget.26090. eCollection 2018 Sep 11. Oncotarget. 2018. PMID: 30323888 Free PMC article. No abstract available.
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
34 results